Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer-Reference-Cited by-同舟云学术

Randomized trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer

Published:2019 Issue: Volume:21 Page:100155
ISSN:2468-2942
Container-title:Cancer Treatment and Research Communications
language:en
Short-container-title:Cancer Treatment and Research Communications

Author:

Gupta Rohan,Cristea Mihaela,Frankel Paul,Ruel Christopher,Chen Chen,Wang Yingyu,Morgan Robert,Leong Lucille,Chow Warren,Koczywas Marianna,Koehler Steve,Lim Dean,Luu Thehang,Martel Cynthia,McNamara Mark,Somlo George,Twardowski Przemyslaw,Yen Yun,Idorenyi Amanam,Raechelle Tinsley,Carroll Mary,Chung Vincent

Funder

National Cancer Institute

National Institutes of Health

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference42 articles.

1. Cancer statistics, 2018;Siegel;CA,2018

2. Tumor angiogenesis: therapeutic implications;Folkman;N. Engl. J. Med.,1971

3. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials;Du Bois;Cancer,2009

4. Oral alkylating agents for breast cancer therapy;O'Shaughnessy;Drugs,1999

5. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer;McGuire;N. Engl. J. Med.,1996

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine;Journal of Oncology Pharmacy Practice;2023-11-28

2. Metronomic chemotherapy in ovarian cancer;Cancer Letters;2023-11

3. A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy;Journal of Oncology Pharmacy Practice;2023-07-27

4. New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis;Biomedicine & Pharmacotherapy;2023-07

5. “DEPHENCE” system—a novel regimen of therapy that is urgently needed in the high-grade serous ovarian cancer—a focus on anti-cancer stem cell and anti-tumor microenvironment targeted therapies;Frontiers in Oncology;2023-06-28